Cronyxin Injection, 5% w/v Solution for Injection

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Flunixin

Available from:

Cross Vetpharm Group Ltd

ATC code:

QM01AG90

INN (International Name):

Flunixin

Pharmaceutical form:

Solution for injection

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Cattle, Horses

Therapeutic area:

Anti Inflammatory NSAID

Authorization status:

Authorized

Authorization date:

1996-03-14

Summary of Product characteristics

Revised: February 2012
AN: 01169/2011
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Cronyxin Injection, 5% w/v Solution for Injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
EACH ML CONTAINS:
ACTIVE SUBSTANCE(S):
mg
Flunixin
50
(as Flunixin Meglumine)
EXCIPIENT(S):
Phenol (as preservative)
5
Sodium Formaldehyde Sulfoxylate (as antioxidant)
2.2
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for Injection.
Clear colourless solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle and horses
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
CATTLE
For the control
of acute inflammation associated with
respiratory disease. It has also been shown to have some
benefit in the treatment of experimental
acute bovine
pulmonary emphysema (Fog fever).
Cronyxin injection may be used as adjunctive therapy in the
treatment of acute mastitis.
HORSES
For the alleviation of inflammation and pain associated with
musculoskeletal disorders.
It is also indicated for the alleviation of visceral pain associated
with
colic.
Page 1 of 6
Revised: February 2012
AN: 01169/2011
4.3
CONTRA-INDICATIONS
Do not exceed the stated dose or duration of treatment.
Use is contra-indicated in animals suffering from cardiac, hepatic or
renal disease, where there is the possibility of gastro-intestinal
ulceration or bleeding, where this is evidence of blood dyscrasia or
hypersensitivity to the product.
Do not administer other NSAIDs concurrently or within 24 hours of
each other.
Avoid intra-arterial injection.
Avoid use in dehydrated, hypovolaemic or hypotensive animals, as
there is a potential risk of increased renal toxicity.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
NSAIDs can cause inhibition of phagocytosis and hence in the
treatment
of inflammatory conditions associated with bacterial
infections, appropriate concurrent antimicrobial therapy should be
instigated.
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
Administer by slow intravenous injecti